Investigators from the CORE-MD Project revealed at the end of August in an article in the European Heart Journal that a majority of new high-risk medical devices that are used to treat heart disease, have been released to the market in the European Union (EU) with insufficient evidence from clinical trials. BioMed Alliance is a partner in the EU funded CORE-MD project that aims to coordinate research and evidence for high-risk medical devices. The new findings indicate that too little information about the safety and performance of new implantable devices may be available for healthcare professionals to make informed decisions on patient care.

Read more in the new press release